Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 B/2, Open-label, Single Arm, Multi-cohort, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-hodgkin's Lymphoma (B-NHL)

Trial Profile

A Phase 1 B/2, Open-label, Single Arm, Multi-cohort, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-hodgkin's Lymphoma (B-NHL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs Lisocabtagene-maraleucel (Primary)
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 02 Feb 2019 This trial has been suspended in Spain and Germany.
    • 09 Jan 2019 Planned number of patients changed from 111 to 110.
    • 09 Jan 2019 Planned End Date changed from 1 Dec 2023 to 11 Dec 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top